KMDA
Price
$7.05
Change
-$0.23 (-3.16%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
420.61M
125 days until earnings call
Intraday BUY SELL Signals
LFCR
Price
$7.89
Change
-$0.33 (-4.01%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
307.79M
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KMDA vs LFCR

Header iconKMDA vs LFCR Comparison
Open Charts KMDA vs LFCRBanner chart's image
Kamada
Price$7.05
Change-$0.23 (-3.16%)
Volume$752
Capitalization420.61M
Lifecore Biomedical
Price$7.89
Change-$0.33 (-4.01%)
Volume$2.47K
Capitalization307.79M
KMDA vs LFCR Comparison Chart in %
KMDA
Daily Signal:
Gain/Loss:
LFCR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KMDA vs. LFCR commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Buy and LFCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (KMDA: $7.28 vs. LFCR: $8.22)
Brand notoriety: KMDA and LFCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 130% vs. LFCR: 186%
Market capitalization -- KMDA: $420.61M vs. LFCR: $307.79M
KMDA [@Pharmaceuticals: Generic] is valued at $420.61M. LFCR’s [@Pharmaceuticals: Generic] market capitalization is $307.79M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, LFCR is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while LFCR’s TA Score has 6 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 5 bearish.
  • LFCR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than KMDA.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а +5.35% price change this week, while LFCR (@Pharmaceuticals: Generic) price change was +21.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

KMDA is expected to report earnings on Mar 18, 2026.

LFCR is expected to report earnings on Jan 01, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($421M) has a higher market cap than LFCR($308M). LFCR has higher P/E ratio than KMDA: LFCR (51.23) vs KMDA (20.74). KMDA YTD gains are higher at: 22.965 vs. LFCR (10.633). KMDA has higher annual earnings (EBITDA): 34.2M vs. LFCR (-8.81M). KMDA has more cash in the bank: 66M vs. LFCR (8.27M). KMDA has less debt than LFCR: KMDA (11.4M) vs LFCR (131M). KMDA has higher revenues than LFCR: KMDA (170M) vs LFCR (129M).
KMDALFCRKMDA / LFCR
Capitalization421M308M137%
EBITDA34.2M-8.81M-388%
Gain YTD22.96510.633216%
P/E Ratio20.7451.2340%
Revenue170M129M132%
Total Cash66M8.27M799%
Total Debt11.4M131M9%
FUNDAMENTALS RATINGS
KMDA vs LFCR: Fundamental Ratings
KMDA
LFCR
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
78100
PRICE GROWTH RATING
1..100
5345
P/E GROWTH RATING
1..100
565
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (72) in the Biotechnology industry is in the same range as LFCR (99) in the Industrial Specialties industry. This means that KMDA’s stock grew similarly to LFCR’s over the last 12 months.

KMDA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that KMDA’s stock grew similarly to LFCR’s over the last 12 months.

KMDA's SMR Rating (78) in the Biotechnology industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that KMDA’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's Price Growth Rating (45) in the Industrial Specialties industry is in the same range as KMDA (53) in the Biotechnology industry. This means that LFCR’s stock grew similarly to KMDA’s over the last 12 months.

LFCR's P/E Growth Rating (5) in the Industrial Specialties industry is somewhat better than the same rating for KMDA (56) in the Biotechnology industry. This means that LFCR’s stock grew somewhat faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDALFCR
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
65%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signal:
Gain/Loss:
LFCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BNPQY40.171.07
+2.74%
BNP Paribas
ELKEF2.60N/A
N/A
Elkem ASA
KNCRF92.10N/A
N/A
Konecranes Plc
BKUT510.00N/A
N/A
Bank of Utica (NY)
ECGS0.28-0.05
-13.90%
Eco-Growth Strategies Inc.

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and OGI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+3.12%
OGI - KMDA
29%
Poorly correlated
-1.83%
LFCR - KMDA
27%
Poorly correlated
+6.20%
SGIOY - KMDA
27%
Poorly correlated
+1.17%
RDY - KMDA
26%
Poorly correlated
+0.29%
CRDL - KMDA
25%
Poorly correlated
N/A
More

LFCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LFCR has been loosely correlated with NBIX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if LFCR jumps, then NBIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+6.20%
NBIX - LFCR
36%
Loosely correlated
-0.30%
SHPH - LFCR
31%
Poorly correlated
-0.79%
AMRX - LFCR
31%
Poorly correlated
-0.42%
ZTS - LFCR
29%
Poorly correlated
+0.94%
KMDA - LFCR
28%
Poorly correlated
+3.12%
More